Sapheneia Commercial Products AB filed for bankruptcy Aug. 28, 2013. Shortly before the company went into bankruptcy, it changed its company name to “Contact Imaging Sweden AB.” In July 2013, the Stockholm District Court ruled that ContextVision is the real owner of a key patent application filed by Sapheneia in September 2006. The court also ruled that Sapheneia should pay the legal costs of ContextVision amounting to TSEK 2,940. The amount has not been paid, and instead, Sapheneia filed for bankruptcy. The administration of the company in bankruptcy has been taken over by a receiver.  

At RSNA 2013, GE will feature its Discovery XR656 digital X-ray system and a suite of advanced clinical applications.

Discovery XR656 digital X-ray system

Conformable GORE® TAG® Thoracic Endoprosthesis


The world of personal pronouns has changed from when I was a kid. “That” has pushed “who” out of the picture, as in “he’s the patient that is showing signs of …” 

Two-dimensional (2-D) digital mammography has been the gold standard for the first line of defense in breast cancer. Yearly mammograms are suggested for women beginning at age 40 and continuing as long as women are in good health. And while 2-D mammograms appear to be sufficient for many women who report no findings on their mammograms, there is much controversy surrounding what the second line of defense should be for those women who require a second look. 

According to many healthcare experts, radiology is facing a perfect storm. This situation has been brought about by a number of factors, all converging on this profession at the present time. The challenges that radiology groups face today are declining reimbursements, expanded patient access, increased quality demands and the emergence of competition from mega groups.

SuperSonic Imagine’s Aixplorer MultiWave Ultrasound system, first cleared by the U.S. Food and Drug Administration (FDA) in 2009, has received FDA clearance for the quantification capabilities of its Real-Time ShearWave Elastography (SWE).

Radiation therapy clinical trial study pelvic cancer diarrhea sulfasalazine

Patients receiving radiotherapy (RT) for cancers in the pelvic region can experience diarrhea, a negative side effect of radiation treatment. Sulfasalazine, an oral tablet used to treat inflammation of the bowels, had been shown in a past trial of 31 patients to decrease diarrhea during pelvic RT. Sulfasalazine does not reduce diarrhea, according to research presented today at the American Society of Radiation Oncology’s (ASTRO’s) 55th Annual Meeting. The study also determined that the medication might be associated with a higher risk of diarrhea than placebo.
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now